Evidence map›Paper›PMID 36012590›Full record

ArticleInternational journal of molecular sciences2022

Harmicens, Novel Harmine and Ferrocene Hybrids: Design, Synthesis and Biological Activity.

Goran Poje, Marina Marinović, Kristina Pavić, Marija Mioč, Marijeta Kralj, Lais Pessanha de Carvalho, Jana Held, Ivana Perković, Zrinka Rajić

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Biological Activity of Amidino-Substituted Imidazo [4,5-Molecules (Basel, Switzerland) · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Goran PojeFaculty of Pharmacy and Biochemistry, University of Zagreb, 10 000 Zagreb, Croatia.
Marina MarinovićFaculty of Pharmacy and Biochemistry, University of Zagreb, 10 000 Zagreb, Croatia.
Kristina PavićFaculty of Pharmacy and Biochemistry, University of Zagreb, 10 000 Zagreb, Croatia.ORCID 0000-0002-8523-6340
Marija MiočLaboratory of Experimental Therapy, Division of Molecular Medicine, Ruder Boškovic Institute, 10 000 Zagreb, Croatia.
Marijeta KraljLaboratory of Experimental Therapy, Division of Molecular Medicine, Ruder Boškovic Institute, 10 000 Zagreb, Croatia.ORCID 0000-0002-7165-2722
Lais Pessanha de CarvalhoInstitute of Tropical Medicine, University of Tübingen, 72074 Tübingen, Germany.
Jana HeldInstitute of Tropical Medicine, University of Tübingen, 72074 Tübingen, Germany.ORCID 0000-0002-7970-1429
Ivana PerkovićFaculty of Pharmacy and Biochemistry, University of Zagreb, 10 000 Zagreb, Croatia.
Zrinka RajićFaculty of Pharmacy and Biochemistry, University of Zagreb, 10 000 Zagreb, Croatia.ORCID 0000-0003-1223-1116
University of Zagreb · HRRuđer Bošković Institute · HRGerman Center for Infection Research · DEUniversity of Tübingen · DE

Funding

Croatian Science Foundation UIP-2017-05-5160Croatian Science Foundation Young researcher's career development project - training of doctoral students
6 · The paper itself

Abstract

Cancer and malaria are both global health threats. Due to the increase in the resistance to the known drugs, research on new active substances is a priority. Here, we present the design, synthesis, and evaluation of the biological activity of harmicens, hybrids composed of covalently bound harmine/β-carboline and ferrocene scaffolds. Structural diversity was achieved by varying the type and length of the linker between the β-carboline ring and ferrocene, as well as its position on the β-carboline ring. Triazole-type harmicens were prepared using Cu(I)-catalyzed azide-alkyne cycloaddition, while the synthesis of amide-type harmicens was carried out by applying a standard coupling reaction. The results of in vitro biological assays showed that the harmicens exerted moderate antiplasmodial activity against the erythrocytic stage of P. falciparum (IC50 in submicromolar and low micromolar range) and significant and selective antiproliferative activity against the MCF-7 and HCT116 cell lines (IC50 in the single-digit micromolar range, SI > 5.9). Cell localization experiments showed different localizations of nonselective harmicene 36 and HCT116-selective compound 28, which clearly entered the nucleus. A cell cycle analysis revealed that selective harmicene 28 had already induced G1 cell cycle arrest after 24 h, followed by G2/M arrest with a concomitant drastic reduction in the percentage of cells in the S phase, whereas the effect of nonselective compound 36 on the cell cycle was much less pronounced, which agreed with their different localizations within the cell.

Indexed as

Antineoplastic AgentsMalaria, FalciparumApoptosisCarbolinesCell Line, TumorCell ProliferationDrug Screening Assays, AntitumorG2 Phase Cell Cycle CheckpointsHarmineHumansMetallocenesStructure-Activity RelationshipAntineoplastic AgentsCarbolinesHarmineMetallocenesamideantiplasmodialantiproliferativeferroceneharminehybridsynthesistriazoleβ-carboline

Identifiers

PMID36012590
PMCPMC9408872
OpenAlexW4292246751

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.